RHU the Pioneer Project | Overcoming resistance to anti-PD1(L1) immunotherapies in lung cancer: first patient enters clinical trial

This randomized clinical trial is one of the cornerstones of The Pioneer Project, a multiparametric study that seeks to understand, predict and overcome resistance to PD1(L1) inhibitors (ICIs, immune checkpoint inhibitors). Coupled with an analysis of biomarkers predictive of this resistance, the randomized multicenter umbrella-type trial includes 4 experimental arms that combine the anti-PDL1 durvalumab (ImfinziTM, AstraZeneca) with four new-generation ICIs. The primary endpoint of the trial is the percentage of patients who at 12 weeks have either a total response to treatment, a partial response, or stable disease.